<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01064479</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0395</org_study_id>
    <secondary_id>NCI-2011-03782</secondary_id>
    <secondary_id>2009-0395</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT01064479</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Phase 2 Study of Docetaxel and Cisplatin/Carboplatin With or Without Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well combination chemotherapy with or without
      erlotinib hydrochloride works in treating patients with squamous cell carcinoma of the head
      and neck that has spread to other parts of the body or has come back. Drugs used in
      chemotherapy, such as docetaxel, cisplatin, and carboplatin, work in different ways to stop
      the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
      stopping them from spreading. Erlotinib hydrochloride may stop the growth of tumor cells by
      blocking some of the enzymes needed for cell growth. Giving combination chemotherapy with or
      without erlotinib hydrochloride may be an effective treatment for squamous cell carcinoma of
      the head and neck.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Assess the efficacy of adding erlotinib hydrochloride (erlotinib) to chemotherapy to
      improve progression free survival in patients with metastatic or recurrent squamous cell
      carcinoma of the head and neck.

      SECONDARY OBJECTIVES:

      I. Evaluate overall survival, response rate, disease control rate, and duration of response
      by treatment with or without erlotinib.

      II. Evaluate quality of life (patient reported outcomes) by treatment with or without
      erlotinib.

      III. Evaluate the safety profile of erlotinib in combination with chemotherapy. IV. Correlate
      the occurrence of erlotinib-induced rash with outcomes. V. To evaluate the steady-state
      pharmacokinetics of erlotinib. VI. To explore the prognostic and predictive value of
      epidermal growth factor receptor related biomarkers and other biomarkers, including blood and
      tissue proteomic and blood and tissue genomic markers, that may be associated with clinical
      outcomes.

      OUTLINE: Patients are randomized to 1 of 2 arms.

      ARM A: Patients receive docetaxel intravenously (IV) over 1 hour and cisplatin IV over 2
      hours or carboplatin IV over 2 hours on day 1, and erlotinib hydrochloride orally (PO) daily
      on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease
      progression and unacceptable toxicity. Patients achieving complete response, partial
      response, or stable disease may continue erlotinib hydrochloride treatment.

      ARM B: Patients receive docetaxel and cisplatin or carboplatin as in Arm I and placebo PO
      daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of
      disease progression and unacceptable toxicity. Patients achieving complete response, partial
      response, or stable disease may continue placebo treatment.

      After completion of study treatment, patients are followed up at 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 5, 2010</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Kaplan-Meier methods will be used to summarize PFS. In the primary analysis, differences in PFS in Arm A versus Arm B will be tested using a stratified log-rank test with a two-sided alpha of 0.10. Hazard ratios for PFS will be presented using point estimates and 95% confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Kaplan-Meier methods will be used to summarize OS. Hazard ratios for OS will be presented using point estimates and 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response (complete response [CR] + partial response [PR])</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Will be estimated by treatment arm with 95% confidence intervals. A logistic regression model will be used to test for treatment differences with terms in the model for treatment, recurrence-free survival, and smoking status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control (CR + PR + stable disease [SD])</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Will be estimated by treatment arm with 95% confidence intervals. A logistic regression model will be used to test for treatment differences with terms in the model for treatment, recurrence-free survival, and smoking status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rash rates</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Will be estimated by treatment arm with 95% confidence intervals. A logistic regression model will be used to test for treatment differences with terms in the model for treatment, recurrence-free survival, and smoking status.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>EGFR status</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Exploratory analyses will be conducted to correlate occurrence of rash and biomarker status with outcomes to treatment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Metastatic Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Metastatic Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Metastatic Squamous Cell Carcinoma of the Oral Cavity</condition>
  <condition>Metastatic Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Recurrent Hypopharyngeal Squamous Cell Carcinoma</condition>
  <condition>Recurrent Laryngeal Squamous Cell Carcinoma</condition>
  <condition>Recurrent Oral Cavity Squamous Cell Carcinoma</condition>
  <condition>Recurrent Oropharyngeal Squamous Cell Carcinoma</condition>
  <condition>Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7</condition>
  <condition>Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7</condition>
  <condition>Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7</condition>
  <condition>Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7</condition>
  <condition>Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <arm_group>
    <arm_group_label>Arm A (combination chemotherapy and erlotinib hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel IV over 1 hour and cisplatin IV over 2 hours or carboplatin IV over 2 hours on day 1 and erlotinib hydrochloride PO daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue erlotinib hydrochloride treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (combination chemotherapy and placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive docetaxel and cisplatin or carboplatin as in Arm I and placebo PO daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue placebo treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (combination chemotherapy and erlotinib hydrochloride)</arm_group_label>
    <arm_group_label>Arm B (combination chemotherapy and placebo)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (combination chemotherapy and erlotinib hydrochloride)</arm_group_label>
    <arm_group_label>Arm B (combination chemotherapy and placebo)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (combination chemotherapy and erlotinib hydrochloride)</arm_group_label>
    <arm_group_label>Arm B (combination chemotherapy and placebo)</arm_group_label>
    <other_name>Docecad</other_name>
    <other_name>RP56976</other_name>
    <other_name>Taxotere</other_name>
    <other_name>Taxotere Injection Concentrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (combination chemotherapy and erlotinib hydrochloride)</arm_group_label>
    <other_name>Cp-358,774</other_name>
    <other_name>OSI-774</other_name>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Optional correlative studies</description>
    <arm_group_label>Arm A (combination chemotherapy and erlotinib hydrochloride)</arm_group_label>
    <arm_group_label>Arm B (combination chemotherapy and placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Optional correlative studies</description>
    <arm_group_label>Arm A (combination chemotherapy and erlotinib hydrochloride)</arm_group_label>
    <arm_group_label>Arm B (combination chemotherapy and placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm B (combination chemotherapy and placebo)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm A (combination chemotherapy and erlotinib hydrochloride)</arm_group_label>
    <arm_group_label>Arm B (combination chemotherapy and placebo)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed metastatic or recurrent squamous cell carcinoma of the head
             and neck (SCCHN) of the oral cavity, oropharynx, hypopharynx or larynx; metastatic or
             recurrent lesions of the nasopharynx and sinus are excluded

          -  Radiologically measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded) as &gt;=
             20 mm with conventional techniques or as &gt;= 10 mm with spiral computed tomography (CT)
             scan; measurable lymph nodes are required to be &gt;= 15 mm in size (short axis diameter)

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) =&lt; 2

          -  Absolute neutrophil count (ANC) &gt;= 1.5 x 10^9/L

          -  Platelet count &gt;= 100 x 10^9/L

          -  Total bilirubin =&lt; upper limit of normal (ULN) (excluding Gilbert's disease)

          -  Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 1.5 x
             ULN

          -  Alkaline phosphatase =&lt; 2.5 x ULN

          -  Serum creatinine =&lt; 1.5 x ULN

          -  Patients with reproductive potential (e.g., females menopausal for less than 1 year
             and not surgically sterilized) must practice effective contraceptive measures for the
             duration of study drug therapy and for at least 30 days after completion of study drug
             therapy; female patients of childbearing potential must provide a negative pregnancy
             test (serum or urine) =&lt; 14 days prior to treatment initiation

          -  Written informed consent to participate in the study according to the investigational
             review board (IRB) or independent ethics committee (IEC)

        Exclusion Criteria:

          -  Histology other than squamous cell carcinoma

          -  Primary sites other than oral cavity, oropharynx, hypopharynx, and larynx

          -  Prior palliative chemotherapy for metastatic or recurrent disease

          -  Prior biological therapy for metastatic or recurrent disease within 3 weeks prior to
             randomization

          -  Patients with known, untreated brain metastases; patients with treated (irradiated or
             resected) brain metastases are eligible if treatment was completed more than 28 days
             prior to study entry and if clinical neurologic function is stable

          -  Pre-existing peripheral neuropathy &gt;= grade 2

          -  History of poorly controlled gastrointestinal disorders that could affect the
             absorption of the study drug (e.g., Crohn's disease, ulcerative colitis); patients
             requiring feeding tubes are permitted

          -  Other active malignancies requiring chemotherapy treatment within 2 years prior to
             randomization, except for adequately treated basal cell or squamous cell skin cancer
             or in situ cervical or breast cancer or superficial, resected melanoma

          -  Serious underlying medical condition which would impair the ability of the patient to
             receive protocol treatment, in the opinion of the treating physician

          -  History of allergic reactions to compounds of similar chemical composition to the
             study drugs (docetaxel, cisplatin, carboplatin, erlotinib or their excipients), or
             other drugs formulated with polysorbate 80

          -  Any concurrent anti-cancer therapy, excluding hormonal therapy for prostate or breast
             cancer

          -  Dementia or significantly altered mental status that would prohibit the understanding
             and giving of informed consent

          -  Women who are pregnant or breast-feeding and women or men not practicing effective
             birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuning Le</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Regional Care Center-Katy</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Regional Care Center-Bay Area</name>
      <address>
        <city>Nassau Bay</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Regional Care Center-Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Regional Care Center-The Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 5, 2010</study_first_submitted>
  <study_first_submitted_qc>February 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2010</study_first_posted>
  <last_update_submitted>April 11, 2020</last_update_submitted>
  <last_update_submitted_qc>April 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

